The NIAID funding supplements a previous award of up to $10 million announced in October 2024 for supporting investigational new drug (IND) and Phase 2 clinical study activities. DARE-HPV is an ...
The move, which will take effect in December, will see Fauci leave his positions as director of the National Institute of Allergy and Infectious Diseases (NIAID) and Chief of the NIAID Laboratory of ...
DARE-HPV is a proposed treatment for HPV-related cervical diseases, supported by up to $2 million in NIAID grants. Daré Bioscience, Inc. has announced the development of DARE-HPV, an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results